Success Metrics

Clinical Success Rate

88.9%

Based on 8 completed trials

Completion Rate

89%(8/9)

Active Trials

1(8%)

Results Posted

100%(8 trials)

Terminated

1(8%)

Phase Distribution

Ph phase_2

50%

Ph phase_1

33%

Ph phase_3

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Phase 1Safety & dosage

4(33.3%)

Phase 2Efficacy & side effects

6(50.0%)

Phase 3Large-scale testing

2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(8)

Terminated(2)

Detailed Status

Completed8

Terminated1

Withdrawn1

Not yet recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.9%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (33.3%)

Phase 26 (50.0%)

Phase 32 (16.7%)

Trials by Status

completed867%

terminated18%

withdrawn18%

not_yet_recruiting18%

active_not_recruiting18%

Recent Activity

1 active trials

Showing 5 of 12

active_not_recruitingphase_1

Study of Midomafetamine in Healthy Adults

NCT07584720

completedphase_2

Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

NCT03485287

completedphase_2

Clinical Trials (12)

Showing 12 of 12 trials

NCT07584720Phase 1

Study of Midomafetamine in Healthy Adults

Active Not Recruiting

NCT03485287Phase 2

Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

Completed

NCT00090064Phase 2

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

Completed

NCT03537014Phase 3

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

Completed

NCT04714359Phase 3

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

Completed

NCT02427568Phase 2

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

Completed

NCT01958593Phase 2

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

Terminated

NCT02008396Phase 2

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

Completed

NCT04030169Phase 2

Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

Completed

NCT04073433Phase 1

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)

Withdrawn

NCT01404754Phase 1

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

Completed

NCT03606538Phase 1

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

Not Yet Recruiting

All 12 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 12